On June 20, 2022 Dxcover Limited, a clinical stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, reported the launch of the Dxcover platform, a ground-breaking platform that transforms Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) spectroscopy to enable faster sample analysis (Press release, Dxcover, JUN 20, 2022, View Source [SID1234616107]). Dr. Matthew Baker, co-founder and Chief Technology Officer, will be presenting an overview of the technology at the 12th International Conference on Clinical Spectroscopy (SPEC) in Dublin, Ireland.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ATR-FTIR spectroscopy is a powerful analytical technique without the need for extensive sample preparation or use of reagents. The traditional ATR method is reliant upon an internal reflection element (IRE), which is often a fixed point of analysis that requires mandatory cleaning steps to avoid cross contamination.
The Dxcover Infrared Platform however is composed of novel hardware items that transform commercial FTIR instruments. Dxcover sample slides are made from microfabricated silicon wafers and replace the single IRE with four sampling areas for one background measurement, and three sample measurements. Additionally, the Dxcover Autosampler can automate sample slide analysis, indexing the slide across the infrared beam without user interaction. Alongside efficiencies in batch processing, the Dxcover approach can be four times faster than standard ATR-FTIR instrumentation, which is optimized for clinical applications.
"Our team is excited to unveil our platform’s unique and innovative hardware at SPEC," said Dr. Baker. "This milestone marks a significant step forward in transforming the use of infrared spectroscopy for a whole host of applications including detecting cancer at an earlier stage, which maximizes the opportunity to combat or control disease progression."
Abstracts being presented at SPEC include:
Clinical validation of a spectroscopic liquid biopsy for early detection of brain cancer
Investigating the effect of inherit protein markers for a spectroscopic liquid biopsy platform
Multi-cancer early detection with a spectroscopic liquid biopsy platform
Machine learning based detection of pancreatic tumors using the Dxcover cancer liquid biopsy
Recurrent Neural Networks for Time Domain Interferogram Modelling
Spinning Out Spectroscopy: Developing the Dxcover Cancer Liquid Biopsy